Stifel Financial Corp raised its holdings in bluebird bio Inc (NASDAQ:BLUE) by 152.1% in the 4th quarter, Holdings Channel reports. The fund owned 6,131 shares of the biotechnology company’s stock after acquiring an additional 3,699 shares during the period. Stifel Financial Corp’s holdings in bluebird bio were worth $600,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. raised its holdings in bluebird bio by 10.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,619,413 shares of the biotechnology company’s stock valued at $674,435,000 after acquiring an additional 422,866 shares during the last quarter. Vanguard Group Inc raised its holdings in bluebird bio by 10.1% in the 3rd quarter. Vanguard Group Inc now owns 4,619,413 shares of the biotechnology company’s stock valued at $674,435,000 after acquiring an additional 422,866 shares during the last quarter. Capital World Investors raised its holdings in bluebird bio by 37.4% in the 3rd quarter. Capital World Investors now owns 3,425,687 shares of the biotechnology company’s stock valued at $500,150,000 after acquiring an additional 931,932 shares during the last quarter. Capital International Investors raised its holdings in bluebird bio by 188.6% in the 3rd quarter. Capital International Investors now owns 3,260,636 shares of the biotechnology company’s stock valued at $476,053,000 after acquiring an additional 2,130,927 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in bluebird bio by 1.2% in the 4th quarter. BlackRock Inc. now owns 2,986,142 shares of the biotechnology company’s stock valued at $296,223,000 after acquiring an additional 34,053 shares during the last quarter.

Shares of NASDAQ BLUE opened at $156.90 on Thursday. bluebird bio Inc has a 52-week low of $87.49 and a 52-week high of $199.70. The firm has a market cap of $8.57 billion, a PE ratio of -14.69 and a beta of 2.62.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Thursday, February 21st. The biotechnology company reported ($2.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.83) by $0.11. bluebird bio had a negative net margin of 1,018.02% and a negative return on equity of 32.15%. The firm had revenue of $19.20 million during the quarter, compared to analysts’ expectations of $9.06 million. During the same period in the prior year, the company earned ($2.52) EPS. The firm’s revenue was up 357.1% on a year-over-year basis. As a group, sell-side analysts predict that bluebird bio Inc will post -11.76 earnings per share for the current fiscal year.

Several brokerages have weighed in on BLUE. Cantor Fitzgerald set a $122.00 price target on bluebird bio and gave the company a “hold” rating in a report on Friday, March 22nd. Canaccord Genuity reissued a “buy” rating and set a $161.00 price objective (down from $250.00) on shares of bluebird bio in a research note on Wednesday, January 23rd. SunTrust Banks lowered their price objective on shares of bluebird bio to $184.00 and set a “buy” rating for the company in a research note on Monday, February 25th. JPMorgan Chase & Co. reissued a “buy” rating on shares of bluebird bio in a research note on Thursday, January 10th. Finally, Zacks Investment Research cut shares of bluebird bio from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. One analyst has rated the stock with a sell rating, nine have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $168.12.

In related news, insider Kory James Wentworth sold 209 shares of the company’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $125.96, for a total transaction of $26,325.64. Following the completion of the sale, the insider now directly owns 4,403 shares of the company’s stock, valued at approximately $554,601.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Davidson sold 2,035 shares of the company’s stock in a transaction on Friday, January 18th. The stock was sold at an average price of $130.05, for a total transaction of $264,651.75. Following the sale, the insider now directly owns 24,276 shares of the company’s stock, valued at $3,157,093.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,824 shares of company stock valued at $4,915,712. 3.00% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2019/04/11/stifel-financial-corp-has-600000-holdings-in-bluebird-bio-inc-blue.html.

bluebird bio Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Recommended Story: QQQ ETF

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.